Biotech Values

[dewophile]

Did you know SNY dropped their offer from 129 and a 5+4 cvr made in January?

no, and there is no news since the phase 1 on the kit asset so I'm not sure what led them to lower the CVR by 3 dollars. Perhaps the tox shown in THRD's phase 1 raised some concern that it could also pop up for BPMC. who knows. anyway, the point of this was to guess what value enta's drug may have. with a zero premium you suggested it is worthless. I explained why I think that thinking was flawed. we may have to just agree to disagree on this one. all the best